PIC/S • Qualification & Validation • GMP Lifecycle
PIC/S PI 006-4 Qualification and Validation Guide
A practical, current guide to the revised PIC/S recommendations: what PI 006-4 covers, how its risk-based lifecycle works, and how to apply its expectations to qualification, process validation, transport, utilities, packaging, test methods, and cleaning.
What Is PIC/S PI 006-4?
PIC/S PI 006-4 is titled Recommendations on Qualification and Validation. It is an inspector-focused and industry-use guide that explains practical expectations for planning, executing, documenting and maintaining qualification and validation activities under GMP. The revised document replaces PI 006-3, the 2007 edition, and is designed to complement GMP requirements rather than act as a standalone substitute for them.
The guide covers more than the familiar IQ, OQ and PQ sequence. Its scope includes a lifecycle approach to facilities, supporting utilities, equipment and systems; process validation and ongoing process verification (OPV); transportation verification; solid-dose packaging validation; supporting utilities; test-method validation or verification; and cleaning validation. It emphasizes the relationship between product and patient risk, process understanding, technical evidence and the site's pharmaceutical quality system.
Use PI 006-4 alongside applicable GMP legislation and guidance in the markets where products are made or supplied. It supports a sound cGMP program, but your organization should confirm how local authorities implement or reference PIC/S recommendations.
PIC/S PI 006-4 Status, Effective Date and Scope
PIC/S announced the revised guide as a replacement for PI 006-3. The official document is dated 1 October 2026 and states that it enters into force on that date. This article reflects the document available on that effective date.
The document's recommendations are framed for active pharmaceutical ingredients, intermediates and finished dosage forms, with specific sections addressing certain product or process situations. It is not a universal protocol template. The manufacturer's intended use, product risks, process knowledge and applicable jurisdiction determine the evidence and controls needed in a given case.
PI 006-4 describes qualification as documented evidence that a facility, utility, equipment item or system is fit for its intended use. Validation is used for processes, cleaning and other processes where evidence is needed to show consistent outcomes. The terms connect, but they are not interchangeable.
Core Principles of the PI 006-4 Approach
- Think in lifecycles. Plan from intended use and requirements through design, installation, operation, routine monitoring, changes and retirement.
- Use quality risk management. Scale scope and testing to the significance of potential impact on patients, product quality, data and process control.
- Build evidence from science and engineering. Document why a test, limit, sample plan, frequency or alternative approach is appropriate.
- Keep traceability. Connect requirements and identified risks to design controls, qualification tests, acceptance criteria, results and final conclusions.
- Define decisions before execution. Protocols should specify responsibilities, test methods, acceptance criteria, data handling and deviation processes before work begins.
- Maintain the qualified or validated state. Routine maintenance, calibration, training, change control, deviation review and periodic assessments sustain the state established at initial qualification.
- Protect trustworthy records. Records should be attributable, legible, contemporaneous, original and accurate, with appropriate review of data integrity.
Risk-based does not mean undocumented or less rigorous by default. It means the site can explain why the chosen scope is suitable for the hazards, complexity, process knowledge and intended use. Connect this work to your quality system and ALCOA+ data integrity practices.
The Validation Master Plan (VMP)
PI 006-4 describes the VMP as a central planning document for a site's qualification and validation program. It should be practical, controlled and specific enough to show the site's strategy, responsibilities, scope and governance. The VMP may be supported by subordinate plans, protocols, procedures and reports, but those documents should fit together as one managed program.
What a useful VMP should explain
- Site and program scope, including relevant products, processes, facilities, utilities, equipment and systems.
- Roles, responsibilities, approval authority, cross-functional involvement and quality oversight.
- The approach to quality risk management, criticality, worst-case rationale and prioritization.
- An inventory or schedule identifying what is in scope, its lifecycle stage, planned work and review or requalification strategy.
- Qualification and validation strategies, including process validation, OPV, revalidation, cleaning validation and other applicable topics.
- Document types, protocol and report templates, acceptance criteria, traceability and record-retention arrangements.
- How changes and deviations are assessed, investigated, approved and linked to the quality system.
- How data integrity is confirmed; PI 006-4 calls for this confirmation to be performed independently by personnel who did not execute the work, as appropriate to the activity.
- How the VMP itself is reviewed, updated and kept aligned with site changes.
A VMP should not be a static inventory or a collection of generic statements. It should help the site make defensible decisions about lifecycle work and identify overdue items, emerging risks and dependencies. Relevant procedures should be defined in approved SOPs.
Qualification of Facilities, Utilities, Equipment and Systems
PI 006-4 retains the familiar qualification stages while recognizing that other sound scientific or engineering approaches may be appropriate in certain circumstances. Its objective is not to force a label onto every task; it is to demonstrate that the facility, utility, equipment or system is suitably installed, operates as intended, and has procedures and controls to keep it in a state of control. The guide names approaches such as ASTM E2500 as potentially applicable when justified.
| Stage | Primary question | Typical evidence |
|---|---|---|
| URS | What must the asset or system do for its intended users and process? | Approved, testable user requirements with criticality and GMP risks. |
| DQ / design review | Does the selected design address the URS, process needs and risk controls? | Design review, drawings, specifications and documented requirement mapping. |
| FAT / SAT | Can useful tests be completed at the supplier or after delivery? | Approved protocols and reports; justified use or repetition of test evidence. |
| IQ | Was it installed according to approved design and supplier requirements? | Installation records, component checks, calibration and supplier documents. |
| OQ | Does it function across the intended ranges and defined operating conditions? | Functional tests, critical parameter ranges, alarms, interlocks and results. |
| PQ | Does it perform as required in representative use? | Testing with production material, qualified substitute or proven equivalent simulation. |
| Periodic review / requalification | Does evidence show it remains in a qualified state? | Risk-based review of changes, maintenance, calibration, deviations and trends. |
URS and DQ: define and verify intended use
The URS should be developed with relevant users and technical functions, such as production, engineering, quality and technical services. Requirements should distinguish essentials from preferences where that helps supplier selection, and identified GMP risks should be assessed. Keep the URS under document control and update it through change control as project knowledge evolves. See the related URS guide.
DQ or a documented design review checks whether the selected design meets the URS and applicable process, product and regulatory needs. It is an opportunity to address risks through design before they become expensive commissioning or qualification problems. The design evidence can include specifications, drawings, materials of construction, functions, capacity and supplier information. See Design Qualification (DQ).
FAT and SAT: use supplier evidence deliberately
Factory Acceptance Testing can help identify missing requirements, faults and documentation gaps before equipment ships. Site Acceptance Testing checks equipment in its installed location. PI 006-4 allows appropriate testing evidence to be leveraged when there is a documented rationale that transport or installation has not affected the tested function. Supplier test evidence should be assessed for configuration match, approved criteria, suitable instruments, complete raw data, deviations and traceability; copying a vendor certificate into a validation package is not an adequate assessment.
IQ, OQ and PQ: demonstrate fit for purpose
IQ verifies that the installation conforms to the design, construction documents and/or manufacturer recommendations. Typical checks include equipment identification, installed components, drawings, manuals, materials where relevant, calibration, and availability of operating and maintenance procedures. Read more in the IQ article.
OQ evaluates critical variables and functions, establishes appropriate operating ranges based on risk, and confirms results against predefined acceptance criteria tied to the URS and design. Test instruments should be identified and calibrated; methods should be authorized; data should be reviewed before the final report. See OQ guidance.
PQ demonstrates that the facility, utility, equipment or system performs as designed and required by the user under representative conditions. PI 006-4 allows production materials, qualified substitutes or simulated product when their equivalent behavior under normal operating conditions has been demonstrated. PQ may overlap with process validation; the combined evidence should still fully address both qualification and process-validation objectives. See the PQ guide.
Formal release from one stage to the next should be authorized. Conditional progression can be justified only where open criteria or deviations are assessed and documented as not significantly affecting the next activity. Qualification also verifies that procedures for operation, maintenance, calibration and cleaning exist and that personnel are trained before the study is closed.
Requalification and continued qualified state
PI 006-4 expects manufacturers to review facilities, utilities, equipment and systems at predetermined intervals. The review may examine changes, maintenance records, quality information, deviations and trends to determine whether extra qualification is needed. Frequency should be justified through quality risk management, including equipment criticality. A string of individually minor changes can amount to a significant cumulative change.
Changes should be assessed, documented and approved under change control. A “like-for-like” replacement may be handled through preventive maintenance only when the equivalence decision is documented, justified and approved by Quality. This lifecycle discipline applies to specialized assets such as pharmaceutical HVAC systems and production equipment.
Process Validation and Ongoing Process Verification
PI 006-4 defines process validation as documented evidence that a process, within specified design parameters, can repeatedly and reliably produce product of the required quality. The program should show that the process establishes and maintains a state of control. Development knowledge, scale-up, technology transfer, process design and the routine control strategy should inform the validation approach.
Prospective, concurrent and retrospective approaches
Prospective process validation is normally expected before commercial batches intended for sale are manufactured. Concurrent validation may be considered in exceptional circumstances, with a rationale and controls appropriate to the risk. Retrospective validation is no longer an acceptable approach in PI 006-4. Legacy processes previously validated under earlier standards should be assessed against current expectations through gap analysis and risk assessment.
PI 006-4 does not set a universal number of validation batches for every product. The number of replicates and sampling intensity should be justified by sound science, process and product understanding, control, and potential variability. Bracketing may be appropriate when scientifically justified and supported by quality risk management. Avoid copying a fixed “three batches” rule without explaining why it is adequate for the specific process.
OPV keeps validation alive after launch
Ongoing Process Verification (OPV) evaluates process performance over time using an appropriate monitoring strategy. The depth of monitoring should reflect process maturity, risk, the chance of variation in critical quality attributes and the potential harm from variation. Reports should conclude whether the process remains in control and identify improvements or revalidation needs.
PI 006-4 says OPV reporting intervals should be risk-based and normally should not exceed one year, while allowing justified extensions in specific circumstances such as infrequent manufacture or a need to reveal slow trends. Shorter reporting intervals may be suitable for high-volume products or emerging adverse trends. Where possible, objective statistical tools should support conclusions.
Process validation is not a one-time event. Changes and site transfers require assessment for their effects on the validated state and regulatory impact. A well-controlled process validation program links development knowledge, initial validation, OPV and revalidation.
Other Qualification and Validation Topics in PI 006-4
Transportation verification
Transportation can expose APIs, intermediates, finished products and samples to temperature, humidity, light, vibration, delays, handling failures or other route-specific risks. PI 006-4 calls for route understanding, documented risk assessment and formal route verification using an approved test protocol before routine use. The study should define relevant conditions, data collection, logger suitability and calibration where applicable, handling of excursions and agreements with transport providers.
Solid-dose packaging validation
For solid-dose products, packaging validation should identify critical process parameters and demonstrate their relationship to package integrity. For example, sealing pressure, temperature and machine speed may affect blister or sachet seal integrity. The protocol should follow the risk assessment and use a test method sensitive enough for the intended purpose. Sterile-product container-closure integrity is addressed elsewhere, including specialized PIC/S guidance.
Supporting utilities
Utilities should be assessed according to their product impact and use. Utilities with direct product impact need controls that address their risks; indirect-impact utilities still need to meet specifications appropriate to their function. Water systems may need attention to seasonal source variation, storage, distribution, microbial control, sanitization, sampling and monitoring. The qualification approach described for URS, FAT, SAT, IQ, OQ and PQ applies, with utility-specific risks and performance evidence.
Test-method validation or verification
Methods used for raw materials, intermediates, finished products or qualification and validation work should be validated or, for applicable compendial procedures, verified as required. PI 006-4 does not restate the full analytical validation framework; consult current method-specific guidance such as ICH Q2(R2), pharmacopoeial requirements and local regulations.
Cleaning Validation Under PI 006-4
Cleaning validation provides evidence that an approved cleaning process reproducibly removes product residues, cleaning agents and relevant microbial contamination to scientifically established limits. It is normally an essential part of contamination control when shared equipment is used. The protocol should follow documented risk assessment and include chemical and microbiological considerations appropriate to the process.
Health-Based Exposure Limits (HBELs) are important inputs when setting carryover limits and assessing risk from cross-contamination. The cleaning strategy should consider the hardest-to-clean equipment and products, residue properties, cleaning agents, sampling recovery and analytical method sensitivity. The selected approach should show that acceptance limits are meaningful, measurable and protective.
Cleaning validation demonstrates reproducibility of the cleaning process. Cleaning verification checks that a particular equipment item is clean, and may be used during the cleaning lifecycle, including when automated cleaning is not feasible or when individual changeover verification is justified. They serve related but different purposes.
PI 006-4 recommends cleaning validation on all equipment unless equipment is truly like-for-like or differences are justified as having no impact on cleaning consistency and that conclusion is practically confirmed. Manual cleaning needs detailed, reproducible instructions and trained operators. Visual inspection is a minimum element, but it generally should be supported by appropriate surface or rinse sampling and a validated analytical method with sensitivity below the residue limit. Find practical details in the Cleaning Validation in Pharmaceuticals guide.
PIC/S PI 006-4 Implementation Checklist
Use this checklist to start a site gap assessment. Tailor it to local regulations, product scope and the quality system; it is not a substitute for the full PIC/S document.
- Confirm applicability. Identify sites, products, processes and assets in scope, and distinguish topics covered by other specialized guidance.
- Update the VMP. Reflect the PI 006-4 lifecycle, responsibilities, inventory, risk approach, documentation, review cadence and transition plan.
- Perform a gap and risk assessment. Prioritize legacy qualifications, process validation, OPV, cleaning, transport and utility systems according to product and patient risk.
- Review URS and design records. Make sure requirements are testable, controlled and traceable to design and qualification evidence.
- Assess supplier evidence. Define when FAT/SAT evidence can be leveraged and what must be repeated after delivery or installation.
- Strengthen protocol quality. Preapprove risk-based test scope, acceptance criteria, instrument calibration, data handling and deviation pathways.
- Link procedures and training. Confirm operating, cleaning, maintenance, calibration and monitoring procedures are available and personnel are trained.
- Revisit process validation strategy. Remove retrospective validation as a method; confirm prospective or exceptional concurrent approaches, with documented batch rationale.
- Establish OPV. Define measures, data sources, statistical methods, review frequency, reporting and escalation triggers.
- Review cleaning limits and evidence. Confirm HBELs, scientifically justified carryover limits, worst-case rationale, sampling and method sensitivity.
- Qualify transport routes and utilities. Document route-specific risks and verify controls before routine use; ensure utility risks are addressed according to impact.
- Maintain the lifecycle. Connect changes, deviations, maintenance, periodic reviews and requalification decisions to the quality system and CAPA process where appropriate.
Preserve an audit-ready record of the gap assessment, owners, due dates, decisions, risk rationale and approvals. For each change, include impact assessment and evidence that the qualified or validated state remains supported.
Common PI 006-4 Implementation Gaps
- Updating the document but not the system. A revised VMP has little value if procedures, training, open actions and ongoing monitoring remain unchanged.
- Using risk assessment as a conclusion only. “Low risk” is not sufficient without identified hazards, controls, rationale and approval.
- Weak traceability. Tests are executed without clear links back to user requirements, design decisions or identified critical risks.
- Vendor evidence accepted without evaluation. Supplier documents may not match the delivered configuration or may lack approved criteria, raw data or deviation closure.
- Fixed batch counts without science. A universal batch number is used without considering process knowledge, variability, risk or sampling.
- OPV treated as an annual paperwork exercise. Reports compile numbers without meaningful trend review, process-control conclusions or actions.
- Retrospective validation left in legacy procedures. Older approaches are not assessed against the revised guide and current GMP expectations.
- Cleaning validation based only on visual inspection. Limits, method sensitivity, recovery, HBEL risk and microbiological concerns are not adequately addressed.
- Lifecycle changes handled informally. Repeated small changes are not reviewed cumulatively, and requalification decisions lack rationale.
- Confusing scope boundaries. PI 006-4 is incorrectly treated as detailed guidance for computerized-system validation or analytical procedure validation.
Where a gap could affect product quality, patient safety or data reliability, investigate it through the site quality system, assess impact and implement effective corrective and preventive actions.
Frequently Asked Questions
1. What is PIC/S PI 006-4?
It is the revised PIC/S Recommendations on Qualification and Validation, providing lifecycle and risk-based guidance for qualification, process validation, OPV, transport, utilities, packaging, test methods and cleaning.
2. When did PIC/S PI 006-4 take effect?
The official PI 006-4 document states an effective date of 1 October 2026, and PIC/S says it supersedes PI 006-3.
3. Does PI 006-4 replace GMP Annex 15?
No. PI 006-4 is a recommendation guide that supplements and explains qualification and validation principles; manufacturers must continue to meet applicable GMP legislation and Annex 15 requirements in their jurisdiction.
4. Does PI 006-4 cover computerized-system validation?
It does not give detailed GMP computerized-system validation guidance. The document points readers to PIC/S GMP Annex 11 for that topic.
5. What should a VMP include under PI 006-4?
A VMP should define program scope, responsibilities, risk strategy, inventory, qualification and validation plans, document controls, acceptance criteria, change and deviation management, data-integrity expectations, and periodic review.
6. Does PI 006-4 require IQ, OQ and PQ for every asset?
It describes these established stages while allowing other scientifically or engineering-based approaches where appropriate. The selected approach must demonstrate fitness for intended use and be justified by risk and documented evidence.
7. How many batches are required for process validation?
PI 006-4 does not set one universal number. The number and sampling plan should be justified using process understanding, product risk, expected variability and evidence of control.
8. Is retrospective process validation acceptable under PI 006-4?
No. PI 006-4 states that retrospective validation is no longer an acceptable approach. Legacy processes should be assessed against current standards using gap analysis and risk assessment.
9. What is the difference between cleaning validation and cleaning verification?
Cleaning validation demonstrates that a cleaning process reproducibly achieves its defined outcome. Cleaning verification tests whether particular equipment has been adequately cleaned at a specific point in the lifecycle.
10. How often should ongoing process verification be reported?
The reporting period should be risk-based and normally should not exceed one year. PI 006-4 allows justified exceptions, for example when products are manufactured infrequently or longer data windows are needed to identify slow trends.
Official References and Further Reading
- PIC/S PI 006-4, Recommendations on Qualification and Validation (effective 1 October 2026)
- PIC/S Publications
- Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ)
- Computerized System Validation in Pharmaceuticals (for computerized-system lifecycle topics outside PI 006-4's detailed scope)
This article is an educational summary, not a substitute for the current official PIC/S document, applicable GMP requirements, or a site-specific quality risk assessment. Confirm national regulatory expectations and the current controlled version before applying a requirement.
.webp)
